FindTrial
Sign In

Netupitant

DRUG6 trials

Sponsors

Karyopharm Therapeutics Inc., M.D. Anderson Cancer Center, OHSU Knight Cancer Institute, Helsinn Healthcare SA, Instituto Brasileiro de Controle do Cancer

Conditions

Chemotherapy-induced Nausea and Vomiting (CINV)JAK inhibitor-naïve myelofibrosisMalignant NeoplasmNauseaNausea Post ChemotherapyTreatment naïve patients with MFVomitingmoderate thrombocytopenia

Phase 2

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
CompletedNCT03040726
M.D. Anderson Cancer CenterMalignant Neoplasm, Nausea, Vomiting
Start: 2017-05-03End: 2022-02-14Updated: 2023-10-17
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
CompletedNCT03097588
OHSU Knight Cancer InstituteMalignant Neoplasm
Start: 2017-04-27End: 2020-03-20Updated: 2021-07-12
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
CompletedNCT03204279
Helsinn Healthcare SAChemotherapy-induced Nausea and Vomiting (CINV)
Start: 2017-08-31End: 2019-09-30Updated: 2024-06-25
Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer
CompletedNCT04669132
Instituto Brasileiro de Controle do CancerNausea Post Chemotherapy
Start: 2020-12-17End: 2022-01-17Updated: 2022-02-23
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
RecruitingCTIS2024-511309-47-00
Karyopharm Therapeutics Inc.JAK inhibitor-naïve myelofibrosis, moderate thrombocytopenia
Start: 2024-07-17Target: 38Updated: 2026-01-27

Phase 3

A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
Active, not recruitingCTIS2023-506139-13-00
Karyopharm Therapeutics Inc.Treatment naïve patients with MF
Start: 2024-01-04Target: 195Updated: 2025-10-09

Related Papers

Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
Journal of Clinical Oncology2022-06-01
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.
2021-01-012 citations